Resveratrol differentially modulates inflammatory responses of microglia and astrocytes

Journal of Neuroinflammation

Volumn 7, Issue , 2010, Pages

  Lu, Xiaofeng ^a   Ma, Lili ^a   Ruan, Lingfei ^a,b   Kong, Yan ^a,b   Mou, Haiwei ^a,b   Zhang, Zhijie ^a   Wang, Zhijun ^d   Wang, Ji M ^c   Le, Yingying ^a,b  

^a Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c NATIONAL CANCER INSTITUTE   (United States)

^d SHANGHAI INSTITUTE OF APPLIED PHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; RESVERATROL; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; MITOGEN ACTIVATED PROTEIN KINASE; STILBENE DERIVATIVE;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG POTENCY; ENZYME PHOSPHORYLATION; INFLAMMATION; MICROGLIA; MOUSE; NEUROPROTECTION; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; ANALYSIS OF VARIANCE; ANIMAL; CELL CULTURE; CELL LINE; CYTOLOGY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GEL MOBILITY SHIFT ASSAY; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; ASTROCYTES; BLOTTING, WESTERN; CELL LINE; CELLS, CULTURED; CYTOKINES; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; INFLAMMATION; LIPOPOLYSACCHARIDES; MICE; MICROGLIA; MITOGEN-ACTIVATED PROTEIN KINASES; NITRIC OXIDE SYNTHASE TYPE II; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STILBENES;

EID: 77955540457     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-7-46     Document Type: Article

References (47)

1. Perry VH, Gordon S. Macrophages and microglia in the nervous system. Trends Neurosc 1988, 11:273-277.
2. Aloisi F. The role of microglia and astrocytes in CNS immune surveillance and immunopathology. Adv Exp Med Biol 1999, 468:123-133.
3. Dong Y, Benveniste EN. Immune function of astrocytes. Glia 2001, 36:180-190. 10.1002/glia.1107, 11596126.
4. Chen Y, Swanson RA. Astrocytes and brain injury. J Cereb Blood Flow Metab 2003, 23:137-149. 10.1097/00004647-200302000-00001, 12571445.
5. McGuire SO, Ling ZD, Lipton JW, Sortwell CE, Collier TJ, Carvey PM. Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons. Exp Neurol 2001, 169:219-230. 10.1006/exnr.2001.7688, 11358437.
6. Gayle DA, Ling Z, Tong C, Landers T, Lipton JW, Carvey PM. Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide. Brain Res Dev Brain Res 2002, 133:27-35. 10.1016/S0165-3806(01)00315-7, 11850061.
7. Qin L, Liu Y, Wang T, Wei SJ, Block ML, Wilson B, Liu B, Hong JS. NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J Biol Chem 2004, 279:1415-1421. 10.1074/jbc.M307657200, 14578353.
8. Matsumoto Y, Ohmori K, Fujiwara M. Microglial and astroglial reactions to inflammatory lesions of experimental autoimmune encephalomyelitis in the rat central nervous system. J Neuroimmunol 1992, 37:23-33. 10.1016/0165-5728(92)90152-B, 1372328.
9. Zeinstra E, Wilczak N, De Keyser J. Reactive astrocytes in chronic active lesions of multiple sclerosis express co-stimulatory molecules B7-1 and B7-2. J Neuroimmunol 2003, 135:166-171. 10.1016/S0165-5728(02)00462-9, 12576238.
10. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
11. Depino AM, Earl C, Kaczmarczyk E, Ferrari C, Besedovsky H, del Rey A, Pitossi FJ, Oertel WH. Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur J Neurosci 2003, 18:2731-2742. 10.1111/j.1460-9568.2003.03014.x, 14656322.
12. Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol 1989, 24:173-182. 10.1016/0165-5728(89)90115-X, 2808689.
13. Merrill JE, Chen IS. HIV-1, macrophages, glial cells, and cytokines in AIDS nervous system disease. FASEB J 1991, 5:2391-2397.
14. Bhat KP, Pezzuto JM. Cancer chemopreventive activity of resveratrol. Ann N Y Acad Sci 2002, 57:210-229.
15. Das DK, Maulik N. Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol Interv 2006, 6:36-47. 10.1124/mi.6.1.7, 16507749.
16. Ates O, Cayli SR, Yucel N, Altinoz E, Kocak A, Durak MA, Turkoz Y, Yologlu S. Central nervous system protection by resveratrol in streptozotocin-induced diabetic rats. J Clin Neurosci 2007, 14:256-260. 10.1016/j.jocn.2005.12.010, 17258134.
17. Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int 2009, 54:111-118. 10.1016/j.neuint.2008.10.008, 2892907, 19041676.
18. de la Lastra CA, Villegas I. Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol Nutr Food Res 2005, 49:405-430. 10.1002/mnfr.200500022, 15832402.
19. Lorenz P, Roychowdhury S, Engelmann M, Wolf G, Horn TF. Oxyresveratrol and resveratrol are potent antioxidants and free radical scavengers: effect on nitrosative and oxidative stress derived from microglial cells. Nitric Oxide 2003, 9:64-76. 10.1016/j.niox.2003.09.005, 14623172.
20. Bi XL, Yang JY, Dong YX, Wang JM, Cui YH, Ikeshima T, Zhao YQ, Wu CF. Resveratrol inhibits nitric oxide and TNF-alpha production by lipopolysaccharide-activated microglia. Int Immunopharmacol 2005, 5:185-193. 10.1016/j.intimp.2004.08.008, 15589480.
21. Candelario-Jalil E, de Oliveira AC, Gräf S, Bhatia HS, Hüll M, Muñoz E, Fiebich BL. Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. J Neuroinflammation 2007, 4:25. 10.1186/1742-2094-4-25, 2100038, 17927823.
22. Kim YA, Kim GY, Park KY, Choi YH. Resveratrol inhibits nitric oxide and prostaglandin E2 production by lipopolysaccharide-activated C6 microglia. J Med Food 2007, 10:218-24. 10.1089/jmf.2006.143, 17651055.
23. Xu J, Drew PD. 9-Cis-retinoic acid suppresses inflammatory responses of microglia and astrocytes. J Neuroimmunol 2006, 171:135-144. 10.1016/j.jneuroim.2005.10.004, 2825699, 16303184.
24. Corradin SB, Mauel J, Donini SD, Quattrocchi E, Ricciardi-Castagnoli P. Inducible nitric oxide synthase activity of cloned murine microglial cells. Glia 1993, 7:255-262. 10.1002/glia.440070309, 7681038.
25. Zhang W, Qin L, Wang T, Wei SJ, Gao HM, Liu J, Wilson B, Liu B, Zhang W, Kim HC, Hong JS. 3-hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity. FASEB J 2005, 19:395-397.
26. Zhu J, Wang O, Ruan L, Hou X, Cui Y, Wang JM, Le Y. The green tea polyphenol (-)-epigallocatechin-3-gallate inhibits leukocyte activation by bacterial formylpeptide through the receptor FPR. Int Immunopharmacol 2009, 9:1126-1130. 10.1016/j.intimp.2009.05.002, 19426837.
27. Zhou YL, Snead ML. Identification of CCAAT/enhancer-binding protein alpha as a transactivator of the mouse amelogenin gene. J Biol Chem 2000, 275:12273-12280. 10.1074/jbc.275.16.12273, 10766866.
28. Kawai T, Akira S. TLR signaling. Semin Immunol 2007, 19:24-32. 10.1016/j.smim.2006.12.004, 17275323.
29. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM. Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology 2000, 119:1209-1218. 10.1053/gast.2000.19458, 11054378.
30. Hahm ER, Cheon G, Lee J, Kim B, Park C, Yang CHL. New and known symmetrical curcumin derivatives inhibit the formation of Fos-Jun-DNA complex. Cancer Lett 2002, 184:89-96. 10.1016/S0304-3835(02)00170-2, 12104052.
31. Calderoni AM, Biaggio V, Acosta M, Oliveros L, Mohamed F, Giménez MS. Cadmium exposure modifies lactotrophs activity associated to genomic and morphological changes in rat pituitary anterior lobe. Biometals 2010, 23:135-143. 10.1007/s10534-009-9274-8, 19894126.
32. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000, 406:782-787. 10.1038/35021228, 10963608.
33. Ortega-Gutierrez S, Molina-Holgado E, Guaza C. Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures. Glia 2005, 52:163-168. 10.1002/glia.20229, 15920730.
34. Waetzig V, Czeloth K, Hidding U, Mielke K, Kanzow M, Brecht S, Goetz M, Lucius R, Herdegen T, Hanisch UK. c-Jun N-terminal kinases (JNKs) mediate pro-inflammatory actions of microglia. Glia 2005, 50:235-246. 10.1002/glia.20173, 15739188.
35. Li Y, Liu L, Barger SW, Mrak RE, Griffin WS. Vitamin E suppression of microglial activation is neuroprotective. J Neurosci Res 2001, 66:163-170. 10.1002/jnr.1208, 11592111.
36. Uesugi M, Nakajima K, Tohyama Y, Kohsaka S, Kurihara T. Nonparticipation of nuclear factor kappa B (NFkappaB) in the signaling cascade of c-Jun N-terminal kinase (JNK)- and p38 mitogen-activated protein kinase (p38MAPK)-dependent tumor necrosis factor alpha (TNFalpha) induction in lipopolysaccharide (LPS)-stimulated microglia. Brain Res 2006, 1073-1074:48-59. 10.1016/j.brainres.2005.12.043, 16457791.
37. Jeng KC, Hou RC, Wang JC, Ping LI. Sesamin inhibits lipopolysaccharide-induced cytokine production by suppression of p38 mitogen-activated protein kinase and nuclear factor-kappaB. Immunol Lett 2005, 97:101-106. 10.1016/j.imlet.2004.10.004, 15626481.
38. Bhat NR, Zhang P, Lee JC, Hogan EL. Extracellular signal-regulated kinase and p38 subgroups of mitogen-activated protein kinases regulate inducible nitric oxide synthase and tumor necrosis factor-alpha gene expression in endotoxin-stimulated primary glial cultures. J Neurosci 1998, 18:1633-1641.
39. Pahan K, Sheikh FG, Khan M, Namboodiri AM, Singh I. Sphingomyelinase and ceramide stimulate the expression of inducible nitric-oxide synthase in rat primary astrocytes. J Biol Chem 1998, 273:2591-2600. 10.1074/jbc.273.5.2591, 9446561.
40. Pawate S, Bhat NR. C-Jun N-terminal kinase (JNK) regulation of iNOS expression in glial cells: predominant role of JNK1 isoform. Antioxid Redox Signal 2006, 8:903-909. 10.1089/ars.2006.8.903, 16771680.
41. Kundu JK, Surh YJ. Molecular basis of chemoprevention by resveratrol: NF-kappaB and AP-1 as potential targets. Mutat Res 2004, 55:65-80.
42. Kundu JK, Surh YJ. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett 2008, 269:243-261. 10.1016/j.canlet.2008.03.057, 18550275.
43. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004, 23:2369-2380. 10.1038/sj.emboj.7600244, 423286, 15152190.
44. Shen Z, Ajmo JM, Rogers CQ, Liang X, Le L, Murr MM, Peng Y, You M. Role of SIRT1 in regulation of LPS- or two ethanol metabolites-induced TNF-alpha production in cultured macrophage cell lines. Am J Physiol Gastrointest Liver Physiol 2009, 296:G1047-G1053. 10.1152/ajpgi.00016.2009, 2696216, 19299582.
45. Youn HS, Lee JY, Fitzgerald KA, Young HA, Akira S, Hwang DH. Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex. J Immunol 2005, 175:3339-3346.
46. Young MR, Yang HS, Colburn NH. Promising molecular targets for cancer prevention: AP-1, NF-kappa B and Pdcd4. Trends Mol Med 2003, 9:36-41. 10.1016/S1471-4914(02)00009-6, 12524209.
47. Kundu JK, Shin YK, Surh YJ. Resveratrol modulates phorbol ester-induced pro-inflammatory signal transduction pathways in mouse skin in vivo: NF-kappaB and AP-1 as prime targets. Biochem Pharmacol 2006, 72:1506-1515. 10.1016/j.bcp.2006.08.005, 16999939.